Bicocca Open Archive

Logo unimib boa
ALBERTI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.368
EU - Europa 8.370
AS - Asia 4.857
SA - Sud America 379
AF - Africa 70
OC - Oceania 31
Continente sconosciuto - Info sul continente non disponibili 15
Totale 27.090
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.138
SG - Singapore 2.160
IT - Italia 1.839
RU - Federazione Russa 1.583
DE - Germania 1.378
CN - Cina 1.215
SE - Svezia 973
IE - Irlanda 881
HK - Hong Kong 680
UA - Ucraina 376
GB - Regno Unito 356
BR - Brasile 325
CA - Canada 202
FI - Finlandia 201
FR - Francia 164
AT - Austria 139
IN - India 138
VN - Vietnam 133
DK - Danimarca 119
ID - Indonesia 116
TR - Turchia 110
JP - Giappone 99
NL - Olanda 83
ES - Italia 58
KR - Corea 57
BE - Belgio 50
AU - Australia 29
ZA - Sudafrica 29
GR - Grecia 24
PL - Polonia 23
PK - Pakistan 19
CH - Svizzera 18
TW - Taiwan 18
IR - Iran 16
MX - Messico 15
AR - Argentina 14
EG - Egitto 13
EU - Europa 13
BD - Bangladesh 12
IL - Israele 12
RO - Romania 12
BG - Bulgaria 11
CZ - Repubblica Ceca 11
HR - Croazia 9
IQ - Iraq 9
PT - Portogallo 9
UZ - Uzbekistan 9
EC - Ecuador 8
CL - Cile 7
HU - Ungheria 7
LV - Lettonia 7
NO - Norvegia 7
PE - Perù 7
PH - Filippine 7
GT - Guatemala 6
KZ - Kazakistan 6
NG - Nigeria 6
SA - Arabia Saudita 6
SI - Slovenia 6
AL - Albania 5
AZ - Azerbaigian 5
CO - Colombia 5
MA - Marocco 5
SC - Seychelles 5
TH - Thailandia 5
VE - Venezuela 5
BH - Bahrain 4
LT - Lituania 4
LU - Lussemburgo 4
MY - Malesia 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
AO - Angola 3
BN - Brunei Darussalam 3
BO - Bolivia 3
JM - Giamaica 3
MD - Moldavia 3
PA - Panama 3
PY - Paraguay 3
ET - Etiopia 2
IS - Islanda 2
JO - Giordania 2
KG - Kirghizistan 2
MT - Malta 2
NZ - Nuova Zelanda 2
TN - Tunisia 2
UG - Uganda 2
UY - Uruguay 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BF - Burkina Faso 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
GE - Georgia 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LI - Liechtenstein 1
Totale 27.087
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.158
Singapore 1.449
Fairfield 860
Dublin 855
Woodbridge 831
Wilmington 790
Chandler 718
Frankfurt am Main 710
Milan 675
Hong Kong 672
Ashburn 626
Houston 533
Dearborn 505
Santa Clara 437
New York 380
Seattle 370
Jacksonville 364
Princeton 330
Cambridge 290
Nanjing 207
Moscow 146
Shanghai 142
Boardman 131
Munich 123
Guangzhou 120
Vienna 114
Jakarta 108
Beijing 96
Lawrence 94
Helsinki 93
Altamura 77
Los Angeles 71
Dong Ket 69
Chicago 66
Hefei 64
Rome 59
Lachine 55
Nanchang 55
San Diego 53
Toronto 53
Andover 52
Shenyang 51
London 46
Carate Brianza 45
Nuremberg 44
Council Bluffs 41
Hebei 40
Tianjin 39
Brussels 38
Hangzhou 38
Tokyo 36
Pune 35
Ottawa 34
Jinan 33
Mountain View 32
Melzo 31
Changsha 29
Kunming 28
Norwalk 28
São Paulo 28
Falls Church 25
Edmonton 24
Florence 22
Turku 22
Zhengzhou 22
Mainz 21
Shangdi 21
Fremont 20
Lappeenranta 20
Washington 20
Dallas 19
Jiaxing 19
The Dalles 19
Lissone 18
Sacramento 16
Bologna 15
Romola 15
Turin 15
Athens 14
Düsseldorf 14
Ningbo 14
Paris 14
Sesto San Giovanni 14
Yuseong-gu 14
Brooklyn 13
Amsterdam 12
Chongqing 12
Kiev 12
San Francisco 12
Baltimore 11
Barcelona 11
Brescia 11
Piraeus 11
Rio de Janeiro 11
Salt Lake City 11
Shenzhen 11
Bari 10
Bergamo 10
Boston 10
Chengdu 10
Totale 17.912
Salva come PNG Salva come JPEG
Nome #
Nelarabine-Induced Neurotoxicity: Reversible Damage not only on Peripheral Nerves 381
Translational Approach to Oxaliplatin Induced Peripheral Neurotoxicity - Neurophysiology: the Link between Bed and Bench "side" 367
Peripheral neuropathy induced by microtubule-targeted chemotherapies: Insights into acute injury and long-term recovery 341
Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings 334
Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)4]PF6 and [Au(P)4]PF6 (P = thp or PTA) Anticancer Complexes 324
High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in rats 316
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics 303
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 266
Role of Organic Transporters 1 and 2 in Cisplatin mediated neurotoxicity 257
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 245
Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity 244
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 242
Guillain-Barré syndrome related to COVID-19 infection 242
Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral neuropathy 238
Human Intravenous Immunoglobulin Alleviates Neuropathic Symptoms in a Rat Model of Paclitaxel-Induced Peripheral Neurotoxicity 238
Topiramate prevents oxaliplatin-related axonal hyperexcitability and oxaliplatin induced peripheral neurotoxicity 235
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS) 232
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings 231
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 225
Molsidomine reduces the severity of Vincristine-induced peripheral neurotoxicity in rats 223
Neuronopathies and polyneuropathies: a ready to use translational neurophysiological protocol in rodent models 216
Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data 212
Ion Channel and Transporter Involvement in Chemotherapy-Induced Peripheral Neurotoxicity 211
The validation of neuroactive drug selection based on combinatorial screening in bortezomib-induced neurotoxicity models. 211
Toxic Medications in Charcot-Marie-Tooth Patients: A Systematic Review 210
Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy 210
Nerve Excitability Testing to Unravel Chemotherapy Induced Peripheral Neurotoxicity (CIPN) Pathogenesis: Altered Axonal Excitability as a Possible Pivotal Event Related to Platinum Compounds and Taxanes 200
Assessment of oxaliplatin-induced peripheral neurotoxicity with different treatment schedules 200
Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue 198
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 196
Study of perpheral neurotoxicity of different doses of oxaliplatin in cd1 mice 196
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 195
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools 195
Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNoms study 193
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 193
Sensory-motor paclitaxel polyneuropathy characterization in a rat model 190
Molsidomide provides neuroprotection against vincristine-induced peripheral neurotoxicity 185
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 184
Severe, reversible nelarabine-induced neuropathy and myelopathy 181
Chemotherapy-induced neuropathy 178
Topiramate possible double efficacy profile: Oxaliplatin-induced peripheral neurotoxicity prevention and anticancer synergic action 177
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 175
An in vivo and in vitro neurophysiological approach to acute and chronic oxaliplatin-induced peripheral neurotoxicity 171
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 170
Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial 169
Animal Models for the Study of Human Central and Peripheral Nervous System Diseases 169
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective 168
Chemotherapy-induced Peripheral Neuropathy 166
Chemotherapy induced peripheral neurotoxicity: Six essential articles for effective future research 166
MR309/E-52862, a first-in-class sigma-1 receptor antagonist, in oxaliplatin-induced peripheral neuropathy. An exploratory Phase II clinical trial 164
Dorsal sural nerve conduction study in the assessment of oxaliplatin induced peripheral neuropathy 163
ACCURATE NEUROPHYSIOLOGICAL MONITORING FOR SENSORY NEUROPATHY IN MOUSE MODELS OF CHEMOTHERAPY INDUCED PERIPHERAL NEUROTOXICITY 162
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 161
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 161
EVALUATION OF THE EFFICACY OF PERIPHAGEN NEUROTROPHIN-3 EXPRESSING VECTOR FOR OXALIPLATIN INDUCED PERIPHERAL NEUROPATHY. 159
Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study 157
Morpho-Functional Characterisation of the Rat Ventral Caudal Nerve in a Model of Axonal Peripheral Neuropathy 156
Neurophysiological examination of dorsal sural nerve 156
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 156
When progressive dysphagia could be related to an “old friend” – a case report 156
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin 155
Platinum-drugs Induced Peripheral Neurotoxicity: clinical course and preclinical evidence 155
Introduction to the Italian section for young neurologists 155
NERVE EXCITABILITY TESTING IN ANIMAL MODELS OF OXALIPLATIN INDUCED PERIPHERAL NEUROTOXICITY: ION CHANNEL DYSFUNCTION AS A POSSIBLE PATHOGENETIC MECHANISM. 155
Guillain–Barré Syndrome Associated with COVID-19 155
Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? 155
Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale 154
Chemotherapy-induced peripheral neurotoxicity–outcome measures: the issue 154
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 153
Morphology meets function to unravel Oxaliplatin Induced Peripheral Neurotoxicity (OIPN) 153
Intravenous Immunoglobulin Preparation Attenuates Pain Behaviors in a Wistar Rat Model of Bortezomib-Induced Peripheral Neuropathy 150
Chemotherapy Induced Peripheral Neurotoxicity (CIPN): neurological burden from a physician and patient point of view 150
Topiramate Prevents Oxaliplatin Neurotoxicity in a rat model 149
ERIBULIN, PACLITAXEL, IXABEPILONE AND VINORELBINE-INDUCED PERIPHERAL NEUROPATHY IN MICE: INSIGHTS IN LONG-TERM RECOVERY 147
Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity 147
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 147
NERVE EXCITABILITY TESTING AS THE LINK BETWEEN ANATOMY AND PHYSIOLOGY: AXONAL EXCITABILITY TESTING TO TEST IN VIVO MECHANISMS OF PERIPHERAL NERVE DAMAGE. 146
Topiramate in Oxaliplatin-Induced Peripheral Neurotoxicity: more than neuroprotection. 146
Addressing the Need of a Translational Approach in Peripheral Neuropathy Research: Morphology Meets Function 146
Ivig Effect In A Wistar Rat Model Of Bortezomib-Induced Peripheral Neuropathy 145
Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity 145
Morphofunctional characterisation of axonal damage in different rat models of chemotherapy-induced peripheral neurotoxicity: the role of nerve excitability testing 144
Erratum to: Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study (Int Arch Occup Environ Health, 10.1007/s00420-017-1237-8) 143
Long-term recovery from chemotherapy-induced neuropathy following paclitaxel, ixabepilone, eribulin and vinorelbine in mice 142
Chemotherapy induced peripheral neurotoxicity: the search for the ideal outcome measure 142
Advanced neurophysiology - a translational approach to neuropathy and neuropathic pain 141
EMG Recordings at Rest to Verify Axonal Hyperexcitability in a Rat Model of Oxaliplatin Induced Peripheral Neurotoxicity 140
How to assess models of oxaliplatin induced peripheral neurotoxicity – a neurophysiological translational approach 139
Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy 139
Responsiveness and Minimal Clinical Important Difference (MCID) of the Total Neuropathy Score clinical and nurse versions in CIPN 139
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 138
Macrophage infiltration in different preclinical models of chemotherapy-induced peripheral neurotoxicity 138
Tackling Oxaliplatin Induced Peripheral neurotoxicity: from bed to bench side and back. 138
Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neuropathy 136
Paclitaxel, but Not Cisplatin, Affects Satellite Glial Cells in Dorsal Root Ganglia of Rats with Chemotherapy-Induced Peripheral Neurotoxicity 135
Sodium-Calcium Exchanger 2: A Pivotal Role in Oxaliplatin Induced Peripheral Neurotoxicity and Axonal Damage? 135
Blood neurofilament light chains as a potential damage marker in chemotherapy-induce peripheral neuropathy rodent models 135
Ghrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent models 134
Supportive care 2030 movement: towards unifying ambitions for global excellence in supportive cancer care—an international Delphi study 130
Oxaliplatin induced peripheral neurotoxicity – a neurophysiological translational approach 130
Totale 18.500
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.313
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.313
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020339 0 0 0 0 0 0 0 0 0 0 267 72
2020/20213.952 184 153 439 367 290 498 470 505 305 265 172 304
2021/20222.010 147 252 179 179 171 165 79 91 112 130 174 331
2022/20233.550 434 806 333 313 272 575 78 193 251 69 121 105
2023/20243.401 112 168 174 158 389 706 623 161 240 94 95 481
2024/20257.908 449 1.032 827 426 789 378 681 327 944 1.207 848 0
Totale 28.851